14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026
IMMX vs COCP: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 17, 2026, Immix Biopharma, Inc. (IMMX) captures the overall head-to-head institutional edge over Cocrystal Pharma, Inc. (COCP) on higher Unified Composite conviction (53.1/100 HOLD vs. 38.7/100 SELL) after splitting the core matrix 5–2 (led by Profitability & Quality, Balance Sheet & Cash Flow), while COCP wins 3–2 across the 6-pillar growth and valuation breakdown. IMMX trades at $7.20 (N/M Forward P/E, 0.0% operating margin) versus COCP at $1.01 (N/M Forward P/E, -3063.6% operating margin).
Growth vs. Quality Trade-Off: IMMX earns the overall head-to-head edge with a stronger Unified Composite Score (53.1/100 HOLD vs. COCP 38.7/100 SELL) and 1.83β · 83% Vol risk profile, whereas COCP leads top-line expansion (+26.9% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
Technical & Structure Timing Caution: IMMX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 37.7); meanwhile COCP trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 50.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on IMMX vs COCP. Trailing 12-month operating profitability (IMMX 0.0% vs COCP -3063.6%) and valuation multiples (IMMX N/M vs COCP N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $18.9M market capitalization and -3063.6% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ IMMX vs COCP Key Questions & Quantitative Answers
As of Nov 17, 2026, Immix Biopharma, Inc. (IMMX) captures the overall head-to-head institutional edge over Cocrystal Pharma, Inc. (COCP) on higher Unified Composite conviction (53.1/100 HOLD vs. 38.7/100 SELL) after splitting the core matrix 5–2 (led by Profitability & Quality, Balance Sheet & Cash Flow), while COCP wins 3–2 across the 6-pillar growth and valuation breakdown. IMMX trades at $7.20 (N/M Forward P/E, 0.0% operating margin) versus COCP at $1.01 (N/M Forward P/E, -3063.6% operating margin). Growth vs. Quality Trade-Off: IMMX earns the overall head-to-head edge with a stronger Unified Composite Score (53.1/100 HOLD vs. COCP 38.7/100 SELL) and 1.83β · 83% Vol risk profile, whereas COCP leads top-line expansion (+26.9% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: IMMX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 37.7); meanwhile COCP trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 50.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
COCP leads the Growth & Scale pillar: IMMX posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with COCP at +26.9% YoY revenue growth and +0.0% YoY earnings growth on $330,000 TTM revenue (N/A gross margin, -3063.6% operating margin). On trailing 12-month operating scale, IMMX generates N/A in USD-normalized revenue versus $330,000 for COCP. In operating R&D and SG&A reinvestment, IMMX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for COCP.
COCP screens cheaper on headline valuation multiples. IMMX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas COCP trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 47.3x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against IMMX (-27.0% ROE) versus COCP (-311.7% ROE) capital efficiency.
In options market volatility and institutional positioning, IMMX carries 49.3% implied volatility (9th %ile, Compressed (<25th %ile)), a 0.05x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.83β · 83% Vol realized risk). By comparison, COCP carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.98β · 54% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.